Healthcare white papers: claims, evidence and FDA limits

A white paper is often the most detailed claim a health company ever makes. A two-line ad says “reduces no-shows”; the white paper explains how, cites the studies, shows the charts and names the outcome. Buyers at practices, hospitals and employers read it precisely because it looks like evidence. That is also why regulators treat it as advertising, and why a weak one does more damage than a weak ad.

This guide is for companies that sell to healthcare buyers: software and AI vendors, device and diagnostics makers, drug companies, labs, billing and staffing firms, wellness vendors. It covers what the FTC expects behind health claims, how to cite studies fairly, the extra limits for FDA-regulated products, and expert authors. For the download form and the follow-up emails, see our separate guide to healthcare lead magnets and gated content. Clinical research sites that publish capabilities documents for sponsors should also read marketing a clinical research site.

The short version

• A white paper is an ad. The FTC Act’s ban on deceptive practices in commerce is not limited to ads aimed at consumers (15 USC 45(a)(1)), and false advertising of drugs, devices and services is a separate violation (15 USC 52).
• Have the evidence before you publish. For health claims, the FTC expects competent and reliable scientific evidence, judged against the whole body of research, not only the studies that agree with you.
• Cite studies the way you would want a competitor to cite them. Say who was studied, how many, for how long, and what the limits were. Do not stretch a pilot, a subgroup or a lab result into a general claim.
• Drug and device makers have tighter limits. Literature and reprints sent by a drug maker are labeling (21 CFR 202.1(l)(2)); “cleared” is not “approved” (21 CFR 807.97); and what you say about a use can make it an intended use (21 CFR 801.4).
• Named experts must be real experts, and paid ones must be disclosed (16 CFR 255.3, 255.5).

Why a B2B white paper is still advertising

Many vendors assume that because the reader is a professional, the rules relax. The statutes do not say that. Section 5 of the FTC Act makes unfair or deceptive acts or practices in or affecting commerce unlawful (15 USC 45(a)(1)). Section 12 makes it unlawful to disseminate a false advertisement to induce the purchase of food, drugs, devices, services or cosmetics (15 USC 52), and section 15 defines a false advertisement as one that is misleading in a material respect, counting what it leaves out as well as what it says (15 USC 55(a)(1)).

A white paper that a sales team sends to prospects, or that sits behind a download form on your website, is a marketing piece for those purposes. The audience can change how a claim is understood, since a clinician reads a hazard ratio differently from a patient, but it does not change whether the claim needs support. A professional reader is also more likely to forward your paper to a colleague, a committee or a patient, so assume it will travel.

What counts as support for a health claim

The FTC’s Health Products Compliance Guidance (December 2022) restates the standard it applies to health-related claims: competent and reliable scientific evidence, which it describes as “tests, analyses, research, or studies that (1) have been conducted and evaluated in an objective manner by experts in the relevant disease, condition, or function to which the representation relates; and (2) are generally accepted in the profession to yield accurate and reliable results.” The evidence must also be sufficient in quality and quantity when weighed against the entire body of relevant research.

Points from the guidance that matter most for a white paper:

• Totality of the evidence. The guidance says advertisers “shouldn’t focus only on research that supports an effect, while discounting research that doesn’t.” If three trials found nothing and one found an effect, your paper cannot present the one as the answer.
• Statistically significant and clinically meaningful. Health claims need statistically significant results, and the guidance adds that significant results must translate to a benefit that is clinically meaningful. A tiny but significant change is not a headline.
• All outcomes, not the winners. Studies that measure several outcomes should report all of them, with an adjustment for multiple comparisons. A post hoc finding is weaker than a planned one.
• Relevance to your product and your claim. The guidance names a common problem: valid studies that do not support the claim actually made. Research on an ingredient, a different device, a different population or a different dose does not automatically carry over.

Non-health claims in the same paper, such as time saved, revenue per visit or reduced no-shows, also need a reasonable basis before you publish. If the number comes from your own customer data, keep the analysis, the date range, which customers were included and why, so you can show it later.

Citing studies fairly

The prescription drug advertising rule at 21 CFR 202.1(e) applies to drug makers, but its list of misleading practices reads like a style guide for anyone who cites research. Under 202.1(e)(6) and (e)(7), an ad is or may be misleading if, among other things, it:

• selects information from published articles in a way that makes a product look safer than has been shown (202.1(e)(6)(iv));
• presents a study as if it represents larger or more general experience than it does (202.1(e)(6)(v));
• uses lab or animal data in a way that suggests clinical significance that has not been shown (202.1(e)(6)(vii));
• uses a quote or paraphrase out of context, or cites references that do not actually support the claim (202.1(e)(6)(ix), (x));
• relies on a study inadequate in design, scope or conduct to support its conclusion (202.1(e)(7)(i));
• uses statistical significance to support a claim that has not been shown to be clinically significant, or leaves out the range around an average (202.1(e)(7)(ii));
• mines data after the fact for findings the study does not soundly support (202.1(e)(7)(iii)).

In practice, a fair citation in a white paper gives the reader enough to judge the study without opening it:

• Who and how many. Population, setting, sample size and length of follow-up.
• What kind of study. Randomized trial, observational study, survey, case series, simulation or internal analysis. Label your own customer analyses as such.
• What was measured. The primary outcome, and whether the number you quote was primary, secondary or exploratory.
• The limits. Use the authors’ own stated limitations; if the paper had none, note the obvious ones (single site, no control group, short follow-up).
• Who paid. If your company funded or ran the study, or employs an author, say so next to the citation.
• Charts that do not distort. Start axes at zero where the size of a change matters, show the comparison group, and do not crop a time series to the best months.

Quote short phrases, not paragraphs, from journal articles unless the article is open access under a license that allows it. Paraphrase and link instead; your readers can click through, and you stay clear of copyright problems.

Device and drug makers: the extra limits

If your company makes an FDA-regulated product, a white paper is not only an FTC question.

• Literature is labeling. For drugs, brochures, literature and reprints descriptive of a drug and disseminated by or on behalf of the manufacturer are labeling under 21 CFR 202.1(l)(2). Treat a white paper the same way: within the approved labeling, with fair balance, and through your promotional review process.
• Cleared is not approved. 21 CFR 807.97 says a 510(k) clearance “does not in any way denote official approval of the device,” and any representation that creates an impression of official approval because of the clearance “is misleading and constitutes misbranding.” Write “FDA-cleared” only when true, and never “FDA-approved” for a cleared device. Our guide to medical device marketing claims covers the wording.
• Your words can create an intended use. Under 21 CFR 801.4, a device’s intended use is shown by objective intent, including labeling claims, advertising matter and oral or written statements by the firm or its representatives. A white paper that promotes a use outside the clearance is evidence of that intent.
• Scientific information on unapproved uses. In January 2025 FDA announced a final guidance on firm-initiated communications to health care providers about unapproved uses of approved or cleared products. Its key tenet is that such a communication should be truthful and non-misleading and present what clinicians need to judge the science, including all material aspects of study design, methods and results, all material limitations, and conflicting conclusions from other scientifically sound studies. The Federal Register notice (January 7, 2025) said the guidance was not for current implementation pending OMB review of its information collection, so check FDA’s guidance page for its current status before relying on it, and keep these pieces separate from promotional white papers.

For prescription products sold to consumers as well as clinicians, see our guide to prescription treatment advertising.

Expert authors, advisory boards and paid voices

A white paper signed by a physician, a pharmacist or a health economist carries more weight, which is why the endorsement guides apply. If the paper presents someone as an expert, their qualifications must actually give them that expertise, and their endorsement must come from an actual exercise of it (16 CFR 255.3(a), (b)). A connection between the author and your company that readers would not expect and that could affect how much weight they give the paper, such as payment, equity, an advisory role or employment, must be clearly disclosed (16 CFR 255.5).

• Put the disclosure on the paper itself, near the author’s name, not only on a landing page.
• Let named authors review the final text, including charts and the summary, before release. A ghostwritten conclusion under an expert’s name is the expert’s statement only if they agree with it.
• If you pay physicians to write, review or present, check your Open Payments reporting duties; see our guide to Open Payments and the Sunshine Act.

Our guide to healthcare influencer marketing covers paid voices on social media.

Customer results inside a white paper

Many vendor white papers end with a customer result: a clinic that cut wait times or a group that raised collections. That section is a case study, with the same rules on typicality, disclosure of what the customer received, and patient data. Our guide to healthcare case studies covers each. Two points specific to white papers:

• One site is an anecdote. If the paper’s evidence section is built on a single customer, say so plainly and do not present the result as what buyers should expect.
• No patient data unless it is properly de-identified or authorized. A practice customer cannot hand you protected health information for your marketing without the HIPAA permissions that apply to it.

Distribution: forms, sales emails and LinkedIn

Where the paper goes changes who has to approve it. A paper behind a form collects contact data, so the form and the follow-up sequence need their own review (see the gated content guide). A paper promoted on LinkedIn must also meet LinkedIn’s healthcare ad rules; our guide to LinkedIn marketing for healthcare companies walks through them. Software vendors with certified health IT have their own disclosure duties in every marketing piece; see our guide to EHR vendor marketing claims.

Version control matters more for a white paper than for an ad, because it lives for years. Put a date and version on the cover, keep the substantiation file next to it, and retire or update the paper when a key study is contradicted, a product’s labeling changes or the customer data behind a number is out of date.

An illustration

A hypothetical scheduling software company drafts a white paper titled “Cut no-shows in half.” The evidence is one 90-day analysis at one customer clinic, plus two published studies on reminder messages in general. Review turns it into a stronger paper: the title becomes a description of the approach rather than a promised result; the customer analysis is labeled as a single-site internal analysis with its dates and baseline; the published studies are described as research on reminders in general, not on this product; a third, published study that found little effect is included; and the clinic’s medical director, who is quoted, is disclosed as having received a discount. Nothing persuasive is lost, and every sentence can now be defended.

Checklist

• Every claim, including the title and charts, has its support listed in a substantiation file kept with the paper.
• Studies are described with population, size, design, primary outcome and limitations.
• Contrary or null studies on the same question are acknowledged.
• No lab, animal, subgroup or post hoc result is presented as a general clinical finding.
• Company funding, employment and author payments are disclosed on the paper.
• Drug and device content went through promotional review; “cleared” and “approved” are used correctly; no unapproved use is promoted.
• Customer results are labeled, typical or qualified, and contain no patient data without permission.
• Short quotes only from non-open-access journals; everything else is paraphrased and linked.
• The paper carries a date, a version and a review date.

How we help

We build lead generation programs for health companies, including white papers and evidence summaries written for clinical and business buyers, with a source file for every claim. See our approach to healthcare lead generation, or browse more guides in health company marketing.

Sources

• 15 USC 45: Unfair methods of competition unlawful; prevention by Commission
• 15 USC 52: Dissemination of false advertisements
• 15 USC 55: Additional definitions (false advertisement)
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.3: Expert endorsements
• 16 CFR 255.5: Disclosure of material connections
• 21 CFR 202.1: Prescription-drug advertisements
• 21 CFR 801.4: Meaning of intended uses
• 21 CFR 807.97: Misbranding by reference to premarket notification
• Federal Register, January 7, 2025: Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products, final guidance

More in Health companies, vendors and employers